After gaining a wealth of industry experience during my undergraduate study at the School of Biomedical Sciences, which spanned biotech, healthcare venture capital firms, and a world leading multinational pharmaceutical company- AstraZeneca, I had successfully ventured into the healthcare industry. My education, enriched with both biomedical and business classes with a minor in EPIN, provided a comprehensive framework that later became instrumental in my professional journey.

Upon graduation, I joined IQVIA management consulting Greater China office, first as an analyst and later promoted to associate consultant. I delved into the intricacies of new product launches, corporate strategy, brand positioning, and commercial due diligence across different therapeutic areas, particularly oncology, respiratory, and cardiovascular diseases.

The transition from academia to industry was challenging but enlightening. What you learn in classrooms provides a foundation, but the practical application of that knowledge in a complex, dynamic industry like healthcare is a different ballgame. We have to help clients navigate their way through the pharma value chain, crafting strategies to ensure the commercial success of their products. The real test was translating academic knowledge into actionable business insights.Currently, as an Associate Consultant at IQVIA, I find great fulfillment in helping pharma clients gauge business insights, design strategy plans, and assisting VC or private equity (PE) clients in asset valuation and deal incubation. The most rewarding moments have been when I have seen my strategies come to life, such as when I witnessed the sales boost after giving a commercial revitalizing strategy for a top MNC dealing with patent expiry of a blockbuster oncology drug, and when a surgical mesh company that I conducted commercial due diligence was successfully listed on the HKEX.

Looking back, I am grateful for my undergraduate programme's support in equipping me with business acumen alongside biomedical science knowledge. This balance has been crucial to my career development and has helped me navigate the challenges of the healthcare industry, which is inevitably the bedrock of my professional journey.

在中大生物醫學學院攻讀理學士課程期間，我在生物科技界、醫療保健創業投資公司和世界領先的跨國製藥公司阿斯利康獲得了豐富的行業經驗，並因此成功進入了醫療保健行業。我所學習的課程豐富多彩，除了生物醫學課程之外，亦有商業課程，還副修了創業創新課程（EPIN），這為我後來的職業生涯提供了一個全面的框架。

畢業後，我加入了 IQVIA 諮詢管理大中華區，最初擔任分析師，後來晉升為副顧問。我在各種不同治療方面，尤其是腫瘤、呼吸系統和心血管疾病，深入研究了新產品發佈、企業策略、品牌定位和商業盡職調查等範疇。

從學術界到行業的轉變可說是充滿了挑戰，但也很有啟發性。課堂上學到的知識為我們打下了基礎，但在醫療保健這樣一個複雜多變的行業中實際運用這些知識，卻是另一回事。我們需要幫助客戶在製藥價值鏈中找到正確的方向，制定戰略以確保產品在商業上取得成功，因此真正的考驗其實在於如何把學術知識轉化為可操作的商業見解。

目前，作為 IQVIA 的副顧問，我為製藥業界客戶獲取商業見解、設計戰略計畫，並協助創業投資或私募股權投資客戶進行資產評估和交易促成，這些工作令我得到極大的滿足感。當中最有成就感的時刻莫過於看到自己的戰略付諸實行，例如一間頂級跨國公司的腫瘤暢銷藥物專利到期，我為他們制定了業務復甦策略，並見證了該公司銷售額大增，另一個例子是我為一間手術網片公司進行商業盡職審查後，該公司成功在港交所上市。

回顧過去，我十分感謝生物醫學理學士課程的支持，讓我在獲取生物醫學知識的同時，還培養了商業頭腦。這種平衡對我的職業發展是相當重要的，幫助我應付醫療保健行業的挑戰，這無疑是我專業發展的基石。

在中大生物医学学院攻读理学士课程期间，我在生物科技界、医疗保健创业投资公司和世界领先的跨国制药公司阿斯利康获得了丰富的行业经验，并因此成功进入了医疗保健行业。我所学习的课程丰富多彩，除了生物医学课程之外，亦有商业课程，还副修了创业创新课程（EPIN），这为我后来的职业生涯提供了一个全面的框架。

毕业后，我加入了 IQVIA 咨询管理大中华区，最初担任分析师，后来晋升为副顾问。我在各种不同治疗方面，尤其是肿瘤、呼吸系统和心血管疾病，深入研究了新产品发布、企业策略、品牌定位和商业尽职调查等范畴。

从学术界到行业的转变可说是充满了挑战，但也很有启发性。课堂上学到的知识为我们打下了基础，但在医疗保健这样一个复杂多变的行业中实际运用这些知识，却是另一回事。我们需要帮助客户在制药价值链中找到正确的方向，制定战略以确保产品在商业上取得成功，因此真正的考验其实在于如何把学术知识转化为可操作的商业见解。

目前，作为IQVIA 的副顾问，我为制药业界客户获取商业见解、设计战略计画，并协助创业投资或私募股权投资客户进行资产评估和交易促成，这些工作令我得到极大的满足感。当中最有成就感的时刻莫过于看到自己的战略付诸实行，例如一间顶级跨国公司的肿瘤畅销药物专利到期，我为他们制定了业务复苏策略，并见证了该公司销售额大增，另一个例子是我为一间手术网片公司进行商业尽职审查后，该公司成功在港交所上市。

回顾过去，我十分感谢生物医学理学士课程的支持，让我在获取生物医学知识的同时，还培养了商业头脑。这种平衡对我的职业发展是相当重要的，帮助我应付医疗保健行业的挑战，这无疑是我专业发展的基石。